Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation
Caleb R. Glassman, Naotaka Tsutsumi, Robert A. Saxton, et al.
Science (2022) Vol. 376, Iss. 6589, pp. 163-169
Open Access | Times Cited: 118

Showing 1-25 of 118 citing articles:

The JAK-STAT pathway at 30: Much learned, much more to do
Rachael L. Philips, Yuxin Wang, HyeonJoo Cheon, et al.
Cell (2022) Vol. 185, Iss. 21, pp. 3857-3876
Open Access | Times Cited: 372
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue Chen, Qinfan Yao, Xinyu Gu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 195
Emerging principles of cytokine pharmacology and therapeutics
Robert A. Saxton, Caleb R. Glassman, K. Christopher García
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 1, pp. 21-37
Open Access | Times Cited: 107
Recent Advances in the Knowledge of the Mechanisms of Leptin Physiology and Actions in Neurological and Metabolic Pathologies
María E. Casado, Roberto Collado-Pérez, Laura M. Frago, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1422-1422
Open Access | Times Cited: 49
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
Michael Bonelli, Andreas Kerschbaumer, Kastriot Kastrati, et al.
Annals of the Rheumatic Diseases (2023) Vol. 83, Iss. 2, pp. 139-160
Open Access | Times Cited: 47
Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis
Robert Roskoski
Pharmacological Research (2023) Vol. 189, pp. 106642-106642
Open Access | Times Cited: 45
The intrinsic substrate specificity of the human tyrosine kinome
Tomer M. Yaron, Brian A. Joughin, Emily M. Huntsman, et al.
Nature (2024) Vol. 629, Iss. 8014, pp. 1174-1181
Open Access | Times Cited: 38
Decoding the functional impact of the cancer genome through protein–protein interactions
Haian Fu, Xiulei Mo, Andrei A. Ivanov
Nature reviews. Cancer (2025)
Closed Access | Times Cited: 2
Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
Robert Roskoski
Pharmacological Research (2022) Vol. 183, pp. 106362-106362
Closed Access | Times Cited: 61
Structural insights into the mechanism of leptin receptor activation
Robert A. Saxton, Nathanael A. Caveney, María Dolores Moya-Garzón, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 31
Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors
Lise T. Jensen, Kathrine E. Attfield, Marc Feldmann, et al.
EBioMedicine (2023) Vol. 97, pp. 104840-104840
Open Access | Times Cited: 31
Structural basis of Janus kinase trans-activation
Nathanael A. Caveney, Robert A. Saxton, Deepa Waghray, et al.
Cell Reports (2023) Vol. 42, Iss. 3, pp. 112201-112201
Open Access | Times Cited: 28
Structural insights into the assembly of gp130 family cytokine signaling complexes
Yi Zhou, Panayiotis E. Stevis, Jing Cao, et al.
Science Advances (2023) Vol. 9, Iss. 11
Open Access | Times Cited: 28
Receptor Elimination by E3 Ubiquitin Ligase Recruitment (REULR): A Targeted Protein Degradation Toolbox
Dirk H. Siepe, Lora K. Picton, K. Christopher García
ACS Synthetic Biology (2023) Vol. 12, Iss. 4, pp. 1081-1093
Open Access | Times Cited: 26
Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Andrew Dunbar, Robert L. Bowman, Young C. Park, et al.
Cancer Discovery (2024) Vol. 14, Iss. 5, pp. 737-751
Open Access | Times Cited: 14
The JAK-STAT pathway: from structural biology to cytokine engineering
You Lv, Jianxun Qi, Jeffrey J. Babon, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 13
JAK inhibitor selectivity: new opportunities, better drugs?
Anniina Virtanen, Francesca Romana Spinelli, Jean Baptiste Telliez, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 10, pp. 649-665
Closed Access | Times Cited: 13
Small molecule drug discovery targeting the JAK-STAT pathway
You Lv, Pengbing Mi, Jeffrey J. Babon, et al.
Pharmacological Research (2024) Vol. 204, pp. 107217-107217
Open Access | Times Cited: 12
Cellular spermine targets JAK signaling to restrain cytokine-mediated autoimmunity
Henan Xu, Xiao Zhang, Xin Wang, et al.
Immunity (2024) Vol. 57, Iss. 8, pp. 1796-1811.e8
Closed Access | Times Cited: 12
Biology and therapeutic targeting of molecular mechanisms in MPNs
Joan How, Jacqueline S. Garcia, Ann Mullally
Blood (2022) Vol. 141, Iss. 16, pp. 1922-1933
Open Access | Times Cited: 36
Mechanism of receptor assembly via the pleiotropic adipokine Leptin
Alexandra Tsirigotaki, Ann Dansercoer, Koen H. G. Verschueren, et al.
Nature Structural & Molecular Biology (2023) Vol. 30, Iss. 4, pp. 551-563
Closed Access | Times Cited: 18
Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis
Naotaka Tsutsumi, Zahra Masoumi, Sophie C. James, et al.
Cell (2023) Vol. 186, Iss. 19, pp. 4189-4203.e22
Open Access | Times Cited: 18
Structure–function of type I and III interferons
Nicole A. de Weerd, Aleksandra Kurowska, Juan L. Mendoza, et al.
Current Opinion in Immunology (2024) Vol. 86, pp. 102413-102413
Closed Access | Times Cited: 7
A novel approach to study multi-domain motions in JAK1’s activation mechanism based on energy landscape
Shengjie Sun, Georgialina Rodriguez, Gaoshu Zhao, et al.
Briefings in Bioinformatics (2024) Vol. 25, Iss. 2
Open Access | Times Cited: 6
Individuals with JAK1 variants are affected by syndromic features encompassing autoimmunity, atopy, colitis, and dermatitis
Michael E. Horesh, Marta Martín-Fernández, Conor Gruber, et al.
The Journal of Experimental Medicine (2024) Vol. 221, Iss. 6
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top